Shares of Sana Biotechnology Inc. (SANA) were up over 300% at $7.50 in after-hours trading on Tuesday, following positive initial results from an investigator-sponsored, first-in-human study of UP421 in type 1 diabetes.
UP421 is an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology. The study, conducted in partnership with Uppsala University Hospital, tests the hypothesis of whether HIP-engineered insulin-producing pancreatic cells can be transplanted safely and help to regain insulin production in individuals with type 1 diabetes without the need for simultaneous treatment with immunosuppressive medicines.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com